Once-daily valacyclovir to reduce the risk


The predefined primary end point was the reduction in transmission of symptomatic genital herpes.Bottom line Once daily valcyclovir (Valtrex) slightly reduces the risk of transmission of herpes simplex virus 2 (HSV-2) to uninfected partners.The susceptible partner was evaluated monthly for clinical signs and symptoms of genital herpes.Results: Clinically symptomatic HSV-2 infection developed in 4 of 743 susceptible partners who were given valacyclovir, as compared with 16 of 741 who were given placebo (hazard ratio, 0.25; 95 percent confidence interval, 0.Our study demonstrates that oral valacyclovir taken by immunocompetent persons with recurrent genital HSV-2 infection significantly reduces the rates of HSV reactivation, subclinical shedding, and transmission of genital herpes to a susceptible partner.23 At each visit, safer sex practices, including the use of.The mean rates of recurrence were 0.Fifty nine patients have to take the drug daily for eight months to prevent one infection.Once-daily valacyclovir to reduce the risk of transmission of genital herpes.Source partners were followed for recurrences of genital herpes; 89 were enrolled in a substudy of HSV-2.The partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo once-daily valacyclovir to reduce the risk for eight once-daily valacyclovir to reduce the risk months.Women swabbed the cervicovaginal, vul- bo-controlled trial, which was designed to deter- var, and perianal regions, and men swabbed the pe- mine whether once-daily valacyclovir could reduce nile skin and perianal area.A 500-mg dose of valacyclovir taken once daily reduced the risks of acquisition.

Valacyclovir the risk to once-daily reduce

once-daily valacyclovir to reduce the risk once-daily valacyclovir to reduce the risk once-daily valacyclovir to reduce the risk